The maintenance question is the one that decides what these drugs cost over a lifetime, and the options are set out in stopping and weight regain. This trial tested a specific one: coming off an injection and onto a daily tablet[1].
Read the outcome carefully, because it is not weight lost. It is the proportion of weight reduction already achieved that was still held at week 52. Participants on orforglipron maintained an estimated 74.7% of their reduction in the first cohort and 79.3% in the second, against 49.2% and 37.6% on placebo — treatment differences of 25.5 and 41.7 percentage points.
The placebo arms are worth dwelling on for a different reason. Around half the lost weight stayed off with no drug at all in the first cohort, and over a third in the second. That is a more optimistic picture of stopping than the regain figures usually quoted, and it is a one-year window — the authors flag the duration as a limitation, and weight regain after stopping continues well beyond twelve months, as the discontinuation evidence and the wider regain literature show.
These are model-based estimates rather than raw observed proportions, using a treatment-regimen estimand that counts participants regardless of what they did afterwards. That is the more honest choice for a maintenance question, since it reflects what happens when someone is put on a tablet rather than what happens if they take it perfectly — the same reasoning behind the estimand in the ACHIEVE-2 trial.
If the approach holds up, the practical appeal is obvious: a swallowed maintenance drug removes needles, cold chain and injection-day scheduling from the long tail of treatment, which is where most of the cost and most of the dropout live. Orforglipron is approved for weight management, as covered in the oral one is approved now, so this is a use case that could arrive quickly.